Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer: A randomized study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 3, 1996, Pages 232-234

  Muhonen, Timo ^a   Jantunen, Ismo ^b   Pertovaara, Hannu ^c   Voutilainen, Leena ^b   Maiche, Abdel ^a   Blomqvist, Carl ^a   Pyrhönen, Seppo ^a   Kellokumpu Lehtinen, Pirkko ^c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Breast cancer; Filgrastim; G CSF; Methotrexate; Mitomycin C; Mitoxantrone

Indexed keywords

METHOTREXATE; MITOMYCIN C; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BONE PAIN; BREAST BIOPSY; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; NEUTROPENIA; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; METHOTREXATE; MIDDLE AGED; MITOMYCIN; MITOXANTRONE; NEOPLASM METASTASIS; RECOMBINANT PROTEINS;

EID: 0029952512     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199606000-00004     Document Type: Article

References (11)

1. Smith IE, Powles TJ. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer. Oncology 1993;50:9-15.
2. Smith IE, Jones AL, O'Brien ME, McKinna JA, Sacks NA, Baum M. Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer 1993;29A:592-5.
3. Marks A, Goodman A, Dougherty S.,Ashford R. Myelosuppression after methotrexate, mitoxantrone, and mitomycin C for treatment of advanced breast cancer. Lancet 1987;1:915.
4. Jodrell DI, Iveson TI, Smith E. Myelosuppression after methotrexate, mitoxantrone, and mitomycin C. Lancet 1987;1:1211.
5. Morton AR, Anderson H, Howell A. Myelotoxicity of methotrexate, mitozantrone, and mitomycin C. Lancet 1987;1:1949.
6. Muhonen TT, Wiklund TA, Blomqvist CP, Pyrhönen SO. Unexpected prolonged myelosuppression after mitomycin-C, mitoxantrone and methotrexate (MMM) therapy. Eur J Cancer 1992;28A:1974-6.
7. Tannock IF, Boyd NN, DeBoer G. A randomised trial of two dose levels of cyclophosphamide, methotrexate, and fluoro-uracil for patients with metastatic breast cancer. J Clin Oncol 1988;6: 1377-87.
8. Blomqvist C, Elomaa I, Rissanen P, Hietanen P, Nevasaari K, Helle L. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration. J Clin Oncol 1993;11:437-73.
9. Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987;317:1490-5.
10. Ejlertsen B, Pfeiffer P, Pedersen D, et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 1993;29A:527-31.
11. A'Hern RP, Ebbs SR, Baum MB. Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br J Cancer 1988;57:615-8.